Featured Research

from universities, journals, and other organizations

Skin cells used to develop possible heart defect treatment in first-of-its-kind study

Date:
February 10, 2011
Source:
Stanford University Medical Center
Summary:
Using skin cells from young patients who have a severe genetic heart defect, scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells -- cardiomyocytes -- allowed the researchers for the first time to examine and characterize the disorder at the cellular level.

Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells -- cardiomyocytes -- allowed the researchers for the first time to examine and characterize the disorder at the cellular level.

In a study to be published online Feb. 9 in Nature, the investigators also report their identification of a promising drug to reverse the heart malfunction -- for which there are currently no decent treatments -- after using these newly created heart cells to check the effects of a plethora of compounds.

The new approach involved converting skin cells to heart cells in a dish by reprogramming them to an embryonic-stem-cell-like state, so that the cells are capable of "differentiating" into a multitude of cell types. The scientists then chemically coaxed these induced pluripotent stem cells to become heart cells. The iPS-cell approach represents a big advance because no good alternative methods for studying human heart malfunction at the cellular level now exist.

"This may be the first time this noninvasive 'disease-in-a-dish' technique has been used successfully to screen for drugs in heart disorders," said Ricardo Dolmetsch, PhD, associate professor of neurobiology and senior author of the study. The study's first author is Masayuki Yazawa, PhD, a postdoctoral researcher in Dolmetsch's lab.

The human heart is a pump made of muscle and consisting of four compartments, or chambers: left and right ventricles and two corresponding atria. These chambers must contract in a coordinated sequence to ensure orderly blood flow. That coordination is mediated by electrical signals from cardiac nodes, which are to the heart's chambers what sparkplugs are to a car engine's pistons. In the aggregate, signals among heart cells generate electromagnetic waveforms that can be visualized on an electrocardiogram.

Nearly a dozen genetic mutations identified in humans are known to cause disruptions in this signaling pattern, resulting in a condition called long QT syndrome. (The name reflects an elongated interval between two portions of the waveform typically observed in an electrocardiogram.) People with LQTS suffer from arrhythmias, or irregular heartbeats, and are vulnerable to ventricular fibrillation, an often fatal state in which heart cells contract chaotically.

Genetically caused LQTS occurs in only about one in 7,000 people. But LQTS is also an all-too-common side effect of numerous approved drugs -- it's the reason the popular painkiller Vioxx (rofecoxib) was removed from the market in December 2006 -- although it's not clear why.

For their Nature study, Dolmetsch and his colleagues turned to patients with Timothy syndrome, one genetic mutation known to cause LQTS. Patients with Timothy syndrome are highly susceptible to ventricular fibrillation and often die at an early age. Another hallmark feature of Timothy syndrome is autism, which is the primary focus of Dolmetsch's research.

The defective gene in Timothy syndrome encodes a protein called a calcium channel. This channel controls the flow across a cell's membrane of calcium, which is crucial to many cellular processes but is especially important in nerve cells, where it modulates electrical signals' propagation over long distances, and in muscle cells including heart cells, where it induces contractions.

Exactly why calcium-channel malfunction in Timothy syndrome patients causes cardiac arrhythmia has not been known. One big reason research into both the causes of and treatments for LQTS in general has lagged is that it's hard to study heart cells, said Dolmetsch. "It would be dangerous and unethical to extract heart cells from a living person with or without cardiac disease," he said. In theory, the gene defect tied to Timothy syndrome could be reproduced in a laboratory mouse, whose heart could then be studied. But in practice, this is a non-starter. While a healthy person's resting heart rate is about 60 beats per minute, a mouse's heart thumps at a rate of 500 times a minute, making the organ useless for analyzing timing deficits that afflict human hearts.

The study marks an exciting use of iPS cells, a relatively new technology that was first introduced in 2006. Dolmetsch and his associates reprogrammed skin cells from two Timothy syndrome patients and five normal individuals first into iPS cells, then into cardiomyocytes. Three distinct varieties of cardiomyocytes -- atrial, ventricular and nodal cells -- were generated in this way from both diseased as well as normal subjects. The three cell subtypes spontaneously clumped into miniature heart-like organs resembling a one-chambered heart.

It was apparent that, in contrast to the average 60 beats per minute of the "miniature hearts" derived from normal subjects' skin cells, those of Timothy syndrome patients beat at about a 30-per-minute rate and showed substantial irregularities. The investigators dissected these tiny organs into their constituent cells and showed that each was composed of atrial, ventricular and nodal cells.

Significantly, Dolmetsch's group found that in the Timothy syndrome-derived ventricular cells, but not atrial or nodal cells, the calcium channels encoded by the mutant gene opened normally to allow calcium flow but stayed open longer than those of normal cells. With special dyes that mirror calcium concentrations, Dolmetsch and his team were able to visually inspect calcium flow in heart cells prepared from Timothy syndrome patients' skin.

"We found that their ventricular cells, although not their atrial or nodal cells, had impaired calcium flow" compared with like cells from normal subjects, said Dolmetsch.

The investigators examined the response of these irregular-beating cells to different drugs that have been reported to affect heartbeat rhythms. When they added one of these drugs -- roscovitine, currently in clinical trials for an unrelated indication -- to the cell-culture medium at the right dose, the deficient calcium flow was restored, and so was the regular heartbeat.

Dolmetsch cautioned that at this point roscovitine should not be considered an adequate treatment for LQTS -- it hasn't been tested for this purpose in living animals, let alone humans, and may have pronounced side effects. Still, he said, it's a promising compound for further drug development. Stanford's Office of Technology Licensing has applied for U.S. patents related to the discovery, and Dolmetsch is starting a new company that intends to license those patents once they're granted.

The study was funded by the National Institutes of Health, the Simons Foundation, the Japan Society for the Promotion of Science, the American Heart Association Western States, and Mrs. Linda Miller, Ben and Felicia Horwitz and Mr. and Mrs. Michael McCafferey. Other co-authors are Brian Hsueh and Xiaolin Jia, former undergraduate students in Dolmetsch's lab now at Princeton University and Baylor College, respectively; Jonathan Bernstein, MD, PhD, clinical assistant professor of pediatrics; and Joachim Hallmayer, MD, associate professor of psychiatry and behavioral science.


Story Source:

The above story is based on materials provided by Stanford University Medical Center. The original article was written by Bruce Goldman. Note: Materials may be edited for content and length.


Journal Reference:

  1. Masayuki Yazawa, Brian Hsueh, Xiaolin Jia, Anca M. Pasca, Jonathan A. Bernstein, Joachim Hallmayer, Ricardo E. Dolmetsch. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature, 2011; DOI: 10.1038/nature09855

Cite This Page:

Stanford University Medical Center. "Skin cells used to develop possible heart defect treatment in first-of-its-kind study." ScienceDaily. ScienceDaily, 10 February 2011. <www.sciencedaily.com/releases/2011/02/110209131820.htm>.
Stanford University Medical Center. (2011, February 10). Skin cells used to develop possible heart defect treatment in first-of-its-kind study. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2011/02/110209131820.htm
Stanford University Medical Center. "Skin cells used to develop possible heart defect treatment in first-of-its-kind study." ScienceDaily. www.sciencedaily.com/releases/2011/02/110209131820.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins